



### **Health, Seniors and Active Living**

Active Living, Indigenous Relations, Population  
and Public Health  
4th Floor; 300 Carlton Street  
Winnipeg MB R3B 3M9  
CANADA  
Phone: (204) 788-6737  
Fax: (204) 948-2040

### **Santé, Aînés et Vie active**

Vie active, Relations avec la communauté autochtone,  
Population et santé publique  
4<sup>e</sup> étage; 300, rue Carlton  
Winnipeg MB R3B 3M9  
CANADA  
Tél. : (204) 788-6737  
Télééc. : (204) 948-2040

June 5, 2018

## **RE: Vaccine Product and Program Updates & Spring Cleaning Reminder**

Dear Health Care Provider:

### **Vaccine Product and Program Updates**

Please note the following changes to publicly-funded vaccines through the Provincial Distribution Warehouse starting spring 2018:

#### **Hepatitis B Pediatric:**

Manitoba (MB) will transition from RECOMBIVAX HB® (5ug) to ENGERIX® B Junior (10ug) for high risk individuals under the age of 11 and those who do not fall within the age indication for Engerix® B Adult (20ug).

- Monovalent hepatitis B vaccines may be used interchangeably, using the dosage and schedules recommended by the manufacturer for the vaccine recipient's age group as per the Canadian Immunization Guide (CIG): <https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-7-hepatitis-b-vaccine.html>

#### **Hepatitis A Vaccines:**

MB will transition from VAQTA® Pediatric (6m to less than 18yrs) to HAVRIX®720 Junior (6m to less than 19yrs) and from VAQTA® (18yrs and older) to HAVRIX®1440 (19yrs and older). **Please note the differences in age indication by product.**

- Monovalent HA vaccines may be used interchangeably. Any HA-containing vaccine indicated for the age of the vaccine recipient will provide an effective booster dose after a first dose of vaccine from a different manufacturer.

#### **Human Papillomavirus (HPV) Vaccine:**

MB will transition from GARDASIL® to GARDASIL®9.

- Whenever possible, the same HPV vaccine should be used to complete a vaccine series. However, if Gardasil®4 is unavailable or the product used is unknown, Gardasil®9 should be used to complete the vaccine series.

**Please avoid any Gardasil®4 wastage whenever possible.**

#### **Quadrivalent Conjugate Meningococcal Vaccines:**

Health Canada has lowered the age indication for Nimenrix® from 12 months to 6 weeks of age. Product currently on hand may be administered according to the new age indication.

- The updated product monograph is available online:  
[https://www.pfizer.ca/sites/g/files/g10045006/f/201802/Nimenrix\\_PM\\_SNDS\\_203844\\_19Feb2018\\_E.pdf](https://www.pfizer.ca/sites/g/files/g10045006/f/201802/Nimenrix_PM_SNDS_203844_19Feb2018_E.pdf)

### Rotavirus Vaccines:

MB is in the process of transitioning from Rotarix® to RotaTeq®. Generally, all infants born on or before February 28, 2018 would be on the 2-dose Rotarix® schedule (administered at 2 and 4 months). Given that the two rotavirus vaccines differ in composition and schedule, **the vaccine series should be completed with the same product whenever possible.**

- If any dose in the series was RotaTeq®, a total of 3 doses should be administered.
- If the first dose was unknown, complete the series with 2 doses of RotaTeq®.
- If the first dose was Rotarix® and Rotarix® is unavailable, complete the schedule with two doses of RotaTeq®.

**Please avoid any Rotarix® wastage whenever possible.**

### SPRING CLEANING – VACCINE RETURNS:

Please use this time to locate all expired vaccine in your refrigerator and arrange with the provincial distribution warehouse to have them returned.

- Manitoba Health, Seniors and Active Living's *Return Policy and Procedure* can be found here: <http://www.gov.mb.ca/health/publichealth/cdc/div/docs/vbrpp.pdf>.
- **Please return all expired influenza vaccine prior to placing your order for this upcoming season.**

Immunization resources are located in Manitoba's Immunization Program Manual at:

<http://www.gov.mb.ca/health/publichealth/cdc/div/manual/index.html>

#### **REMINDER REGARDING TESTING FOR MUMPS**

Mumps disease is continuing throughout Manitoba with over 1900 confirmed cases since September 2016.


The testing of suspected clinical cases of mumps is to be conducted by:

- Buccal swab for symptomatic cases. The swab should be taken from the opening of the parotid duct after 30 seconds of massaging the affected parotid gland and placed in viral transport medium. Oral, throat, or nasopharyngeal swabs are not acceptable for this test. Swabs from the parotid duct are best collected within 5 days of parotitis onset; results of Mumps RT-PCR are usually available within 2-5 working days. Culture can take 10 days.
- Serology (Mumps IgM and IgG; Red-top tubes to collect serum) should be done, in addition to buccal swab, where the suspected case is beyond 5 days since symptom onset.
- Urine samples are not necessary during this outbreak.
- **Please provide clinical signs and symptoms and the date of onset on the CPL General Requisition.**
- **Please remember to review the case and family contacts vaccination history for mumps and immunize those with an incomplete vaccination history**

If you have any further questions regarding these matters, please contact Communicable Disease Control at 204-788-6737.

Thank you for your cooperation.

Sincerely,



Richard Baydack, PhD  
**Director**  
**Communicable Disease Control**  
**Health, Seniors & Active Living**



Tim Hilderaman, MD FRCPC  
**Medical Lead, Vaccines**  
**Communicable Disease Control**  
**Health, Seniors & Active Living**